Drug Resistant Epilepsy, Ketogenic Dieting
Conditions
Keywords
ketogenic diet, epilepsy, drug resistance
Brief summary
This is a multicenter, prospective, observational, longitudinal study designed to describe the therapeutic value of the KetoCal® range in the maintenance of a ketogenic diet during the management of infants (from 5 months) and children up to 17 years of age (i.e. 18 years minus 1 day) with drug-resistant epilepsy. This study is being conducted according to standard medical practice. No change in diagnostic or therapeutic management habits is imposed by this study. Quality of life questionnaires are the only additional procedures for this research.
Detailed description
NUTRICIA has developed the KetoCal® range (4:1 and 3:1), a food for special medical purposes (DADFMS), to help healthcare professionals and patients establish and maintain a CR. KetoCal® 4:1 features a 4:1 ratio of fat to (carbohydrate + protein), while containing vitamins, minerals, trace elements and fiber. Similarly, KetoCal® 3:1 has a 3:1 ratio of lipids / (carbohydrates + proteins), while containing vitamins, minerals, trace elements and fiber. The KetoCal® range can be consumed orally, as a drink after dilution in hot water, incorporated as an ingredient in a recipe or administered by enteral feeding tube. The KEOPS study is designed to gather real-life data on the therapeutic value of using the KetoCal® range in the management of drug-resistant epilepsy in infants (from 5 months) and children up to 18 years of age. Patients will be managed according to standard care practices. Initiation of ketogenic dieting will be at the investigator's discretion during the child's hospitalization.
Interventions
OTHERKetocal
ketogene diet
Sponsors
Euraxi Pharma
Nutricia Nutrition Clinique
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
5 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Infants from 5 months and children up to 17 years of age (maximum 18 years minus 1 day). * With drug-resistant epilepsy according to ILAE (International League Against Epilepsy) criteria: persistence of epileptic seizures after failure of two appropriate antiepileptic drugs tried consecutively or in well-tolerated combination. * Indication for CR by a physician. * Parents (or legal guardians) able to set up and follow the diet, assessed during a joint doctor-dietician consultation. * Written authorization from one (or both) parents or the child's legal representative to collect personal information about their child. * Affiliation of the infant/child with the social security system.
Exclusion criteria
* Contraindication to ketogenic diet at initial assessment. * Children already on a ketogenic diet. * Parenteral nutrition. * Concurrent prescription of other foodstuffs intended for special medical purposes (DADFMS) such as KetoVie or Keyo. * Protected legal representative (under legal protection, or deprived of liberty by judicial or administrative decision). * Legal representative not covered by a social security scheme. * Legal representative unable to understand study protocol. Ancillary study eligibility criteria : * Patients included in the study. * Continued on the ketogenic diet for at least 2 months. * Having consented to participate in the ancillary study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of compliance | 6 months | Retention rate which is defined as the proportion of patients who have continued KD for up to 6 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of KD | From Month 1 to Month 6 | Describe the efficacy of KD. Efficacy is defined as responders to KD with seizure frequency reduced by more than 50%, or no seizure frequency in the case of total response to CR in the last week. |
| KD tolerance. | From inclusion to Month 6 | Describe KD tolerance as a number of AE reported |
| Duration of compliance | From Month 1 to Month 6 | Describe the duration of KD compliance. |
| Influence of KD | From inclusion to Month 6 | Total number of antiepileptic drugs used for each child including their current treatment until the end of the study. |
| Ketosis achievement | From inclusion to Month 6 | Evaluate the time it takes to achieve ketosis. Ketosis will be assessed by ketonuria or ketonemia, depending on the habits of each center. |
| QoL evolution | From inclusion to Month 6 | Describe changes in patients' quality of life following initiation of KD at inclusion, and M6; using PedsQL ™ questionnaires |
Countries
France
Contacts
Primary ContactElmire DEGOUL-COMBESCOT, PhD
Outcome results
None listed